Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 1
2016 1
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

3 results
Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Your search for Pharmacokinetics and Pharmacodynamics of the Reverse Transcriptase Inhibitor Tenefovir and Prophylactic Efficacy against HIV-1 Infection retrieved no results
Pharmacokinetics and pharmacodynamics of the reverse transcriptase inhibitor tenofovir and prophylactic efficacy against HIV-1 infection.
Duwal S, Schütte C, von Kleist M. Duwal S, et al. PLoS One. 2012;7(7):e40382. doi: 10.1371/journal.pone.0040382. Epub 2012 Jul 11. PLoS One. 2012. PMID: 22808148 Free PMC article.
Antiviral pre-exposure prophylaxis (PrEP) through daily drug administration can protect healthy individuals from HIV-1 infection. ...Pharmacokinetics were coupled to an HIV model and viral decay following TDF mono-therapy was predicted, consiste …
Antiviral pre-exposure prophylaxis (PrEP) through daily drug administration can protect healthy individuals from HIV-1 infe
Multiscale Systems-Pharmacology Pipeline to Assess the Prophylactic Efficacy of NRTIs Against HIV-1.
Duwal S, Sunkara V, von Kleist M. Duwal S, et al. CPT Pharmacometrics Syst Pharmacol. 2016 Jul;5(7):377-87. doi: 10.1002/psp4.12095. Epub 2016 Jul 21. CPT Pharmacometrics Syst Pharmacol. 2016. PMID: 27439573 Free PMC article.
While HIV-1 continues to spread, the use of antivirals in preexposure prophylaxis (PrEP) has recently been suggested. Here we present a modular systems pharmacology modeling pipeline, predicting PrEP efficacy of nucleotide reverse transcripta
While HIV-1 continues to spread, the use of antivirals in preexposure prophylaxis (PrEP) has recently been suggested. Here we …
Natural substrate concentrations can modulate the prophylactic efficacy of nucleotide HIV reverse transcriptase inhibitors.
García-Lerma JG, Aung W, Cong ME, Zheng Q, Youngpairoj AS, Mitchell J, Holder A, Martin A, Kuklenyik S, Luo W, Lin CY, Hanson DL, Kersh E, Pau CP, Ray AS, Rooney JF, Lee WA, Heneine W. García-Lerma JG, et al. J Virol. 2011 Jul;85(13):6610-7. doi: 10.1128/JVI.00311-11. Epub 2011 Apr 27. J Virol. 2011. PMID: 21525346 Free PMC article.
Macaques received prophylactic GS7340 treatment 3 days prior to each virus exposure. At 3 days postdosing, TFV-DP concentrations in peripheral blood mononuclear cells (PBMCs) were about 50-fold higher than those seen with TFV disoproxil fumarate (TDF), and they remained ab …
Macaques received prophylactic GS7340 treatment 3 days prior to each virus exposure. At 3 days postdosing, TFV-DP concentrations in p …
Feedback